Organic Active Ingredients TRIZ Cases

Anti-MDR1 antibodies bind the MDR1 efflux pump to block drug transport from cancer cells.

A mouse model with human prostate xenografts enables rapid evaluation of test agents targeting vascular endothelial cells.

Selective pyridine and pyrazine compounds modulate the CB2 receptor to reduce inflammation while minimizing central nervous system side effects.

Heating and cooling ethanol dissolves the compound to yield Form A crystals, resolving limited treatment effectiveness.

Novel 1-sulfonyl piperidine derivatives modulate prokineticin receptors to treat psychiatric and neurological conditions.

Sprayable fibrillar collagen powder with monosaccharides enables rapid hemostasis without complex preparation.

Chemically modified AT2 receptor agonists mitigate fibrosis while reducing CYP enzyme inhibition and side effects.

Direct ocular application of high-concentration L-lysine treats feline herpesvirus while avoiding systemic arginine toxicity.

Selective 15-PGDH inhibitors resolve efficacy and specificity trade-offs by regulating prostaglandin levels for treating colon tumors.

Dry mechanical coating of minor API components with nano-sized powders improves blend flowability and bulk density without complex granulation steps.

Novel substituted azetidine dihydrothienopyridines resolve the therapeutic window trade-off by maintaining efficacy while reducing nausea and emesis.

Novel hydroxamate triterpenoid derivatives bind PHD2 to stabilize HIF proteins and activate the pathway.

Lipid formulations containing defined ratios of juniperonic acid and other bioactive fatty acids enhance therapeutic efficacy for human consumption.

Antisense oligonucleotides block PRC2 binding to relieve MECP2 repression and upregulate protein levels.

A probiotic composition uses specific Lactobacillus and Bifidobacterium strains to modulate immune responses.

Engineered chimeric costimulatory receptors improve solid tumor therapy by enabling robust lymphocyte expansion with reduced donor cell requirements.

miR-223-3p inhibits PARP1 expression via mRNA degradation, exploiting BRCA mutations to eliminate tumor viability while sparing normal tissue.

Starch-based matrices replace gelatin in fast dissolving dosage forms, eliminating viscosity issues and reducing production costs.

U2 snRNP inhibitors block PHF5A restriction to boost adeno-associated virus infectivity and gene expression efficiency.

An osmotic pump system delivers lacosamide at a controlled rate to reduce peak-to-trough fluctuations and enable once daily administration.

Micellar dispersion delivers vitamin D3 alongside magnesium carbonate and oxide salts in an oral supplement.

Engineered linker regions in chimeric receptor binding proteins resist proteolytic digestion, ensuring stable DNA delivery into target bacterial cells.

Combines PD-1 antagonists with benzo[b]thiophene STING agonists to induce type I interferon production for enhanced anti-tumor immune responses.

Pyrrolidine-substituted flavones inhibit cyclin-dependent kinases to increase apoptosis, reducing radiation toxicity and overcoming tumor hypoxia resistance.

Induced T regulatory cells enhance bone morphology and reduce fracture rates in osteogenesis imperfecta by substituting chemical drugs with cellular mediators.

Spiro bicyclic compounds disrupt the menin-MLL interaction to block HOXA gene expression and prevent leukemia progression.

A modified release solid dosage form uses a water-soluble barrier coating to control drug delivery kinetics.

siRNA targets fidgetin-like 2 to accelerate wound closure by boosting fibroblast activity.

Layered polymer-inorganic nanogranules improve oil solubility and coating film formation without excessive manufacturing complexity.

Repurposing antimalarial compounds reduces development time while maintaining efficacy against Marburg and Ebola viruses.

Organic arsenical compounds reduce systemic toxicity while maintaining effective anti-proliferative activity against solid and hematological tumors.

Formula I compounds selectively inhibit TYK2 through localized structural interactions, reducing off-target effects from JAK2 inhibition.

Serum-free CHO cell culture eliminates animal-derived virus contamination and non-human glycosylation risks in CMAB008 production.

Probiotic compositions modulate gastrointestinal microbiota to treat pancreatic ductal adenocarcinoma, addressing limited therapeutic options.

A pharmaceutical composition containing a GPCR19 agonist treats allergic dermatitis by modulating immune responses.

Combining CRAF and ERK inhibitors suppresses MAPK signaling to treat BRAF mutant NSCLC with improved efficacy.

Topical brimonidine at 0.3% to 10% concentration treats erythema while limiting systemic exposure and ocular side effects.

A hyaluronic acid derivative incorporates amino acid amides and steryl groups to enhance blood retention.

Antisense oligonucleotides silence specific enhancer RNAs to reduce cancer stemness and tumor propagation in glioblastoma.

DLL3 modulators deplete tumor initiating cells to prevent relapse and metastasis in proliferative disorders.

Coupling an HDM-2 binding agent with a membrane resident component induces necrosis in cancer cells while sparing normal tissue.